“…To ensure the future workforce of pharmacists is adequately prepared to care for patients with kidney disease and improve consistency in practice across the United States, more robust education and practice standards are needed. While these standards have recently been published, 21,22 implementing them into routine practice and education will be key next steps to advancing care for patients with kidney disease.…”
Section: Discussionmentioning
confidence: 99%
“…These include the identification of MTPs using the Pharmacy Quality Alliance (PQA) MTP Categories Framework, 19 and MTP resolution using the PQA MTP Resolution monitoring metric. 20 21,22 implementing them into routine practice and education will be key next steps to advancing care for patients with kidney disease.…”
Introduction: New payment models have intensified the importance of providing comprehensive medication management (CMM) to patients with chronic kidney disease. While some practices have pharmacists integrated into their kidney care teams, increasing the presence of pharmacists providing CMM will be key to practices achieving kidney-related care outcomes and taking advantage of emergent valuebased payment models. To support future practices, the objective of this study was to understand what an ideal practice providing CMM to patients with kidney disease would look like from the perspective of those already in practice.Methods: Qualitative semi-structured interviews were carried out with 11 pharmacists practicing in diverse settings where kidney care was provided. Transcripts were coded deductively using a CMM practice management framework to determine the state of current practice, limitations, and components of an ideal practice.Results: Some components of an ideal CMM practice that were coded include alternative methods of CMM billing and revenue capture, incorporating methods for identifying CMM patients beyond a referral-based system, and having collaborative practice agreements in place. Barriers cited by those currently in practice include not always having support staff available for CMM, and a lack of processes in place to consistently and frequently measure CMM outcomes.
Conclusion:While this study outlined several of the components that would contribute to an ideal practice providing CMM to patients with kidney disease, it also revealed that many existing CMM practices face practice management barriers or limitations. Given the rising importance of providing CMM to patients with kidney disease, a number of implementation supports are now under development. Utilization of these supports will be key to expanding and optimizing CMM services thereby meeting the public health need of improving kidney health and reducing health care costs.
“…To ensure the future workforce of pharmacists is adequately prepared to care for patients with kidney disease and improve consistency in practice across the United States, more robust education and practice standards are needed. While these standards have recently been published, 21,22 implementing them into routine practice and education will be key next steps to advancing care for patients with kidney disease.…”
Section: Discussionmentioning
confidence: 99%
“…These include the identification of MTPs using the Pharmacy Quality Alliance (PQA) MTP Categories Framework, 19 and MTP resolution using the PQA MTP Resolution monitoring metric. 20 21,22 implementing them into routine practice and education will be key next steps to advancing care for patients with kidney disease.…”
Introduction: New payment models have intensified the importance of providing comprehensive medication management (CMM) to patients with chronic kidney disease. While some practices have pharmacists integrated into their kidney care teams, increasing the presence of pharmacists providing CMM will be key to practices achieving kidney-related care outcomes and taking advantage of emergent valuebased payment models. To support future practices, the objective of this study was to understand what an ideal practice providing CMM to patients with kidney disease would look like from the perspective of those already in practice.Methods: Qualitative semi-structured interviews were carried out with 11 pharmacists practicing in diverse settings where kidney care was provided. Transcripts were coded deductively using a CMM practice management framework to determine the state of current practice, limitations, and components of an ideal practice.Results: Some components of an ideal CMM practice that were coded include alternative methods of CMM billing and revenue capture, incorporating methods for identifying CMM patients beyond a referral-based system, and having collaborative practice agreements in place. Barriers cited by those currently in practice include not always having support staff available for CMM, and a lack of processes in place to consistently and frequently measure CMM outcomes.
Conclusion:While this study outlined several of the components that would contribute to an ideal practice providing CMM to patients with kidney disease, it also revealed that many existing CMM practices face practice management barriers or limitations. Given the rising importance of providing CMM to patients with kidney disease, a number of implementation supports are now under development. Utilization of these supports will be key to expanding and optimizing CMM services thereby meeting the public health need of improving kidney health and reducing health care costs.
“…The reader is also directed to the proposed nephrology pharmacy practice standards. 25 Figure 1 Interplay between education and practice standards. Abbreviations: CMM, comprehensive medication management; KDIGO, Kidney Disease Improving Global Outcomes.…”
Section: Akhomm Initiativementioning
confidence: 99%
“…These standards should be considered in conjunction with the practice standards for pharmacists. 25 2. Design prevention, treatment, and patient education strategies for the common comorbid conditions in patients with CKD that incorporate evidence-based pharmacologic and nonpharmacologic treatment options and that address disparities in care.…”
Section: Education Standards For Pharmacistsmentioning
“…The evolution of the role of community pharmacists from substance- or product-oriented services to patient-centered services has given rise to the creation of the discipline of pharmaceutical care. This involves the management of acute situations such as chlamydia testing [ 40 ] and emergency contraception [ 29 ], and chronic diseases such as diabetes [ 41 ], arterial hypertension [ 42 ], HIV/AIDS, [ 43 ], hyperlipidemia [ 44 ], asthma [ 45 ], kidney disease [ 46 ], urinary tract infection [ 47 ], and depression [ 48 ]. There is also potential for pharmacist expertise in palliative care [ 49 ] and organ transplantation [ 50 ].…”
Section: Other Roles Of Pharmacists In Healthcarementioning
This review looks at the factors that may influence practice in the future. Transformation could occur at 3 levels. Firstly, the traditional profession of the pharmacist as a dispenser of medicines is expanding. Secondly, the pharmacist’s activities are progressing into new healthcare fields. Thirdly, other changes are stimulated by global developments. This review may be helpful for pharmacy and healthcare leaders looking at the future configuration and aims of their pharmacy services.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
